BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chang LC. The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal 2019;27:671-8. [PMID: 31324283 DOI: 10.1016/j.jfda.2019.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bogolepova AN. [Cerebrolysin in the treatment of cognitive impairment]. Zh Nevrol Psikhiatr Im S S Korsakova 2023;123:20-5. [PMID: 36946392 DOI: 10.17116/jnevro202312303120] [Reference Citation Analysis]
2 Kolbe AR, Kearsley A, Merchant L, Temkin E, Patel A, Xu J, Jessup A. Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey. BioDrugs 2021;35:363-72. [PMID: 33826078 DOI: 10.1007/s40259-021-00479-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Santos-Neto JF, Oliveira FO, Hodel KVS, Fonseca LMS, Badaró R, Machado BAS. Technological Advancements in Monoclonal Antibodies. ScientificWorldJournal 2021;2021:6663708. [PMID: 33628140 DOI: 10.1155/2021/6663708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Perpoil A, Grimandi G, Birklé S, Simonet JF, Chiffoleau A, Bocquet F. Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant? Int J Environ Res Public Health 2020;18:E186. [PMID: 33383867 DOI: 10.3390/ijerph18010186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Bianconi D, Herac M, Posch F, Schmeidl M, Unseld M, Kieler M, Brettner R, Müllauer L, Riedl J, Gerger A, Scheithauer W, Prager G. Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Ther Adv Med Oncol 2020;12:1758835920928635. [PMID: 32922518 DOI: 10.1177/1758835920928635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]